REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

05/03/2025 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250305:nRSE5120Za&default-theme=true

RNS Number : 5120Z  AstraZeneca PLC  05 March 2025

5 March 2025

 

 

Transactions by Persons Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announced that, on 4 March 2025, certain Persons
Discharging Managerial Responsibilities of the Company (PDMRs) were granted
awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under
the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca
Performance Share Plan (AZPSP), as detailed in the table below.

 

 PDMR            Position                                        Ordinary Shares granted under the AZDBP  Ordinary Shares granted under the AZPSP  Award price per Ordinary Share
 Pascal Soriot   Executive Director and Chief Executive Officer  14,623                                   109,781                                  £119.63
 Aradhana Sarin  Executive Director and Chief Financial Officer  6,243                                    45,494                                   £119.63

 

The AZDBP award represents the portion of each PDMR's annual bonus for 2024
that they are required to defer into shares. The Ordinary Shares granted under
the AZDBP are subject to a three-year holding period and are due to vest on
the third anniversary of grant.

 

The AZPSP award is subject to a combination of performance measures focused on
scientific, commercial, financial and sustainability performance. The
performance measures will be assessed over a three-year performance period (1
January 2025 to 31 December 2027). The Ordinary Shares granted under the AZPSP
are subject to a two-year holding period following the performance period, and
are due to vest on the fifth anniversary of grant.

 

Details of the performance measures attached to the AZPSP award can be found
in the Directors' Remuneration Report within the AstraZeneca Annual Report and
Form 20-F Information 2024, which is available on the Company's website at
www.astrazeneca.com/annualreport2024
(https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2024.html)
.

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Pascal Soriot

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Grants of share awards under the AstraZeneca Performance Share Plan and the

                                                            AstraZeneca Deferred Bonus Plan

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   £119.63   124,404
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      4 March 2025

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

4 March 2025

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Aradhana Sarin

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification/Amendment                               Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Grants of share awards under the AstraZeneca Performance Share Plan and the

                                                            AstraZeneca Deferred Bonus Plan

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   £119.63   51,737
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      4 March 2025

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

4 March 2025

f)

 

Place of the transaction

 

Outside a trading venue

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUVOSRVUUORAR